Key terms

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AXSM news

May 08 6:54am ET Axsome Therapeutics price target lowered to $106 from $109 at Mizuho by TipRanks May 07 11:56pm ET Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials by TipRanks May 07 9:35am ET Buy Rating Affirmed on Axsome Therapeutics Due to Strong Auvelity Sales and Promising Alzheimer’s Treatment Pipeline by TipRanks May 07 8:10am ET Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS), Axsome Therapeutics (AXSM) and Rocket Pharmaceuticals (RCKT) by TipRanks May 07 8:06am ET Axsome Therapeutics (AXSM) Gets a Buy from RBC Capital by TipRanks May 07 7:49am ET Buy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic Positioning by TipRanks May 07 5:22am ET Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM) by TipRanks May 06 8:59pm ET Axsome Therapeutics price target lowered to $125 from $127 at Citi by TipRanks May 06 8:19pm ET Buy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion Potential by TipRanks May 06 7:05am ET Axsome Therapeutics announces anticipated milestones by TipRanks May 06 7:03am ET Axsome Therapeutics expects cash to fund operations into cash flow positivity by TipRanks May 06 7:03am ET Axsome Therapeutics reports Q1 EPS ($1.44), consensus ($1.20) by TipRanks May 01 7:19am ET Axsome Therapeutics recognizes May as Mental Health Awareness Month by TipRanks Apr 29 4:40am ET Axsome Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley by TipRanks Apr 26 2:10am ET Buy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performance by TipRanks Apr 18 1:07am ET Strong Buy on Axsome’s Auvelity Amidst Competitive MDD Market by TipRanks Apr 16 2:56am ET Auvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeutics by TipRanks Apr 08 10:10pm ET Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM) by TipRanks Apr 02 6:26am ET Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential by TipRanks Apr 01 7:17am ET Axsome Therapeutics initiates ENGAGE Phase 3 trial of solriamfetol by TipRanks Mar 28 6:39am ET Axsome Therapeutics price target raised to $109 from $108 at Mizuho by TipRanks Mar 26 8:45am ET Truist Financial Remains a Buy on Axsome Therapeutics (AXSM) by TipRanks Mar 26 6:40am ET Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC) by TipRanks Mar 26 6:16am ET Buy Rating Affirmed for Axsome Therapeutics with Increased Target Price Following Strong AXS-12 Trial Results by TipRanks Mar 26 4:55am ET Maintaining Hold on Axsome Therapeutics: Weighing AXS-12’s Modest Efficacy Against Competitive and Market Risks by TipRanks Mar 25 9:20pm ET Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE) by TipRanks Mar 25 7:05am ET Axsome Therapeutics announces results of CRESCENDO narcolepsy survy by TipRanks Mar 25 6:34am ET Axsome Therapeutics says AXS-12 achieves primary endpoint in SYMPHONY trial by TipRanks Mar 20 6:30am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Mar 19 7:03am ET Axsome Therapeutics initiates PARADIGM Phase 3 trial of Solriamfetol by TipRanks Mar 19 1:37am ET Axsome Therapeutics’ Auvelity Rebounds: A Buy Rating Reinforced by Prescription Growth and Market Resilience by TipRanks

No recent press releases are available for AXSM

AXSM Financials

1-year income & revenue

Key terms

AXSM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AXSM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Bruce Garelick was found guilty of insider trading
John Minchillo/AP
Investor found guilty in Trump Media insider trading case
People walk toward an entrance to Disneyland in Anaheim, California on April 24, 2023.
Mario Tama/Getty Images/File
Americans are shopping less but they’re still spending on flights, hotels and Disneyland
Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg
Michael Nagle/Bloomberg/Getty Images
For US renters, the chance of owning a home is going from bad to worse
Close-up detail of the Disney+ app icon on an Apple iPhone 12 Pro smartphone screen, on November 11, 2020. (Photo by Phil Barker/Future Publishing via Getty Images)
Phil Barker/Future Publishing/Getty Images
Disney just had its worst day in a year and a half